Cabergoline
- Generic Name
- Cabergoline
- Brand Names
- Dostinex
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37N5O2
- CAS Number
- 81409-90-7
- Unique Ingredient Identifier
- LL60K9J05T
- Background
Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
- Indication
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
- Associated Conditions
- Hyperprolactinemia, Idiopathic hyperprolactinemic disorder
- Associated Therapies
- Inhibition of physiological lactation
Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- KK Women's and Children's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT01535859
- Locations
- 🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore
Cabergoline Effect on Blood Sugar in Type 2 Diabetics
- Conditions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Mashhad University of Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT01459601
Effect of Cabergoline on Weight and Glucose Tolerance
- Conditions
- Interventions
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 40
- Registration Number
- NCT01395602
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Conditions
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT01278342
- Locations
- 🇮🇹
Novarts Investigative Site, Naples, Italy
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2010-06-14
- Target Recruit Count
- 20
- Registration Number
- NCT01143584
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India
Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2009-11-17
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 19
- Registration Number
- NCT01014793
- Locations
- 🇧🇷
Federal University of Sao Paulo, Sao Paulo, SP, Brazil
Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program
- Conditions
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01009567
- Locations
- 🇮🇷
Endocrinology and Female Infertility Department, Reproductive Medicine Research Center, Royan institute, ACECR, Tehran, Iran, Islamic Republic of
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Seth Gordhandas Sunderdas Medical College
- Registration Number
- NCT00889525
- Locations
- 🇮🇳
Seth GSMC & KEM hospital, Mumbai, Maharashtra, India
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00652873
- Locations
- 🇨🇦
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00653055
- Locations
- 🇨🇦
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.